Toshiba America Medical Systems has sharply focused its U.S. ultrasoundproduct efforts. The vendor has ended the sales of scanners intosuch markets as ob/gyn and urology--which were channeled throughdealers--in order to focus its own direct sales efforts
Toshiba America Medical Systems has sharply focused its U.S. ultrasoundproduct efforts. The vendor has ended the sales of scanners intosuch markets as ob/gyn and urology--which were channeled throughdealers--in order to focus its own direct sales efforts on radiologyand cardiology, according to Daniel Dugan, vice president forultrasound business operations.
"We cover the (U.S.) market with dedicated ultrasoundpeople and no distributors," Dugan told SCAN.
Trimming its product line will help TAMS avoid customer confusionabout what scanners are meant for which markets. The strategywill also let the vendor concentrate ultrasound advertising, marketingand sales resources on the two dominant user groups in this market,he said.
"We may come back to the ob/gyn market, for instance,but with a product designed and built for the U.S. market anda dedicated organization set up to sell it," Dugan said.
TAMS has expanded its ultrasound sales and service staff tofocus on these two large market segments. Although some short-termrevenue was sacrificed by the shift of products, overall ultrasoundrevenue will have grown 45% to 50% in fiscal 1991 (end-March).This makes TAMS the fastest growing ultrasound company in theU.S., he said.
Toshiba is readying the seventh software revision for its 270high-end ultrasound scanner, which should be available by May.A unique feature of the upgrade is independent beam steering forgray-scale imaging, spectral Doppler and color-flow Doppler, saidThomas Jedrzejewicz, director of marketing.
Gray-scale imaging is optimized when the beam runs perpendicularto the vessel. However, vessels do not always run parallel tothe skin, he noted. Color-flow Doppler, on the other hand, requiresits own approach to the vessel for optimization of the flow velocitymap.
Emerging PET/CT Agent Shows Promise in Detecting PCa Recurrence in Patients with Low PSA Levels
February 13th 202518F-DCFPyL facilitated detection of recurrent prostate cancer in 51 percent of patients with PSA levels ranging between 0.2 to 0.5 ng/ml, according to new research presented at the American Society of Clinical Oncology Genitourinary Cancers (ASCO-GU) Symposium.
Emerging MRI Scoring System May Help Predict Recurrent and Metastatic Hepatocellular Carcinoma
February 12th 2025Preoperative use of the scoring system for gadoxetic acid-enhanced MRI demonstrated an average AUC of 85 percent and average specificity of 89 percent in external validation cohorts for pathologic features of hepatocellular carcinoma.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.